Exelixis (EXEL)
22.70
0.00 (0.00%)
Upcoming Events
Latest Headlines
Barclays Downgrades Exelixis (EXEL) to Equalweight
April 11, 2024 2:54 AM - StreetInsider
Form 8-K EXELIXIS, INC. For: Mar 27
March 29, 2024 4:15 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Mar 21 Filed by: Garber Alan M
March 25, 2024 7:31 PM - SEC Filing
Form 144 EXELIXIS, INC. Filed by: Garber Alan M
March 21, 2024 4:06 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Peterson Amy C.
February 27, 2024 6:59 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Aftab Dana
February 27, 2024 6:59 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: MORRISSEY MICHAEL
February 27, 2024 6:59 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Senner Christopher J.
February 27, 2024 6:58 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Hessekiel Jeffrey
February 27, 2024 6:58 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Haley Patrick J.
February 27, 2024 6:58 PM - SEC Filing
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 27, 2024 4:05 PM - BizWire
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
February 23, 2024 6:35 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Feb 21 Filed by: Caligan Partners LP
February 22, 2024 5:09 PM - SEC Filing
Form 4 EXELIXIS, INC. For: Feb 15 Filed by: Aftab Dana
February 16, 2024 7:21 PM - SEC Filing
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024 8:30 AM - StreetInsider
Form SC 13G/A EXELIXIS, INC. Filed by: VANGUARD GROUP INC
February 13, 2024 5:35 PM - SEC Filing
Form SC 13G EXELIXIS, INC. Filed by: RENAISSANCE TECHNOLOGIES LLC
February 13, 2024 9:20 AM - SEC Filing
Exelixis (EXEL) PT Raised to $28 at RBC Capital
February 7, 2024 7:07 AM - StreetInsider
Form 10-K EXELIXIS, INC. For: Dec 29
February 6, 2024 4:52 PM - SEC Filing
Form 8-K EXELIXIS, INC. For: Feb 06
February 6, 2024 4:29 PM - SEC Filing
Exelixis (EXEL) Tops Q4 EPS by 10c, offers guidance
February 6, 2024 4:13 PM - StreetInsider
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
February 6, 2024 4:05 PM - BizWire
Exelixis (EXEL) PT Raised to $25 at Stifel
February 2, 2024 7:47 AM - StreetInsider
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 1, 2024 4:05 PM - BizWire
Exelixis (EXEL) PT Raised to $25 at Barclays
January 30, 2024 4:23 AM - StreetInsider
Exelixis (EXEL) Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial of Cabozantinib in Combination with Atezolizumab
January 25, 2024 8:00 AM - StreetInsider
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU
January 25, 2024 8:00 AM - BizWire
Form SC 13G/A EXELIXIS, INC. Filed by: BlackRock Inc.
January 24, 2024 9:48 AM - SEC Filing
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
January 23, 2024 4:05 PM - BizWire
Bristol-Myers Squibb (BMY) and Exelixis (EXEL) Announce Opdivo with CABOMETYX Demonstrated Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial
January 22, 2024 5:01 PM - StreetInsider
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell
January 22, 2024 5:00 PM - BizWire
Exelixis (EXEL) Reports EU Patent Office Ruled in Favor of Exelixis on Formulation Patent Covering CABOMETYX
January 18, 2024 4:07 PM - StreetInsider
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
January 18, 2024 4:05 PM - BizWire
Exelixis (EXEL) PT Raised to $28 at Wells Fargo
January 17, 2024 5:55 AM - StreetInsider
Full Article List
